Diagnosis of niemann-pick C1 by measurement of bile acid biomarkers in archived newborn dried blood spots

被引:20
|
作者
Jiang, Xuntian [1 ]
Sidhu, Rohini [1 ]
Orsini, Joseph J. [2 ]
Farhat, Nicole Y. [3 ]
Porter, Forbes D. [3 ]
Berry-Kravis, Elizabeth [4 ]
Schaffer, Jean E. [1 ]
Ory, Daniel S. [1 ]
机构
[1] Washington Univ, Sch Med, Diabet Cardiovasc Dis Ctr, St Louis, MO 63110 USA
[2] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA
[3] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Mol Dysmorphol, NIH, DHHS, Bethesda, MD 20892 USA
[4] Rush Univ, Med Ctr, Chicago, IL 60612 USA
关键词
Niemann-pick C disease; Biomarker; Bile acid; Newborn screening; DISEASE TYPE-C; CHOLESTANE-3-BETA; 5-ALPHA; 6-BETA-TRIOL; PROGRESSION; MIGLUSTAT; ONSET;
D O I
10.1016/j.ymgme.2018.08.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Niemann-Pick disease type Cl (NPC1) is a rare, neurodegenerative cholesterol storage disorder. Diagnostic delay of > 5 years is common due to the rarity of the disease and non-specific early symptoms. To improve diagnosis and facilitate early intervention, we previously developed a newborn screening assay based on newly identified plasma bile acid biomarkers. Because the newborn screen had been validated using dried blood spots (DBS) from already diagnosed NPC1 patients, an unanswered question was whether the screen would be able to detect individuals with NPC1 at birth. Methods: To address this critical question, we obtained the newborn DBS for already diagnosed NPC1 subjects (n = 15) and carriers (n = 3) residing in California, New York, and Michigan states that archive residual DBS in biorepositories. For each of the DBS, we obtained two neighbor controls DBS from patients born on the same day and in the same hospital as the NPC1 patients and carriers. 3 beta,5 alpha,6 beta-trihydroxycholanic acid (bile acid A) and trihydroxycholanic acid glycine conjugate (bile acid B) were measured in the DBS using a liquid chromatography -tandem mass spectrometry (LC-MS/MS) assay. Results: Bile acid B, the more specific biomarker for which the fully validated DBS assay was developed, was detected in 8/15 NPC1 patients, and elevated above the cut-off in 2/15 patients (the two samples with the shortest storage time). Bile acid B was detected in 2/2, 6/10, and 0/7 NPC1 samples that have been stored for < 10.5 years, 13-20 years, and > 20 years, respectively, indicating that the glycine conjugate is detectable in DBS but may have reduced long-term stability compared with bile acid A, the precursor trihydroxycholanic acid, which was elevated in 15/15 NPC1 subjects, but not in carriers and controls. Conclusions: These results demonstrate that newborn screening for NPC1 disease is feasible using bile acid biomarkers.
引用
收藏
页码:183 / 187
页数:5
相关论文
共 50 条
  • [21] Increased Regenerative Capacity of the Olfactory Epithelium in Niemann-Pick Disease Type C1
    Meyer, Anja
    Wree, Andreas
    Guenther, Rene
    Holzmann, Carsten
    Schmitt, Oliver
    Rolfs, Arndt
    Witt, Martin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (04):
  • [22] A differential proteomics study of cerebrospinal fluid from individuals with Niemann-Pick disease, Type C1
    Li, Wenping
    Pergande, Melissa R. R.
    Crutchfield, Christopher A. A.
    Searle, Brian C. C.
    Backlund, Peter S. S.
    Picache, Jaqueline A. A.
    Burkert, Kathryn
    Yanjanin-Farhat, Nicole M. M.
    Blank, Paul S. S.
    Toth, Cynthia L. L.
    Wassif, Christopher A. A.
    Porter, Forbes D. D.
    Cologna, Stephanie M. M.
    PROTEOMICS, 2023, 23 (11)
  • [23] Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1)
    Tortelli, Brett
    Fujiwara, Hideji
    Bagel, Jessica H.
    Zhang, Jessie
    Sidhu, Rohini
    Jiang, Xuntian
    Yanjanin, Nicole M.
    Shankar, Roopa Kanakatti
    Carillo-Carasco, Nuria
    Heiss, John
    Ottinger, Elizabeth
    Porter, Forbes D.
    Schaffer, Jean E.
    Vite, Charles H.
    Ory, Daniel S.
    HUMAN MOLECULAR GENETICS, 2014, 23 (22) : 6022 - 6033
  • [24] Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status
    Hung, Ya Hui
    Walterfang, Mark
    Churilov, Leonid
    Bray, Lisa
    Jacobson, Laura H.
    Barnham, Kevin J.
    Jones, Nigel C.
    O'Brien, Terence J.
    Velakoulis, Dennis
    Bush, Ashley I.
    NEUROTHERAPEUTICS, 2016, 13 (03) : 614 - 622
  • [25] Therapeutic potential of histone deacetylase inhibitor for treatment of Niemann-Pick type C1 disease
    Nina H Pipalia
    Frederick R Maxfield
    Molecular Cytogenetics, 7 (Suppl 1)
  • [26] Current controversies in Niemann-Pick C1 disease: steroids or gangliosides; neurons or neurons and glia
    Erickson, Robert P.
    JOURNAL OF APPLIED GENETICS, 2013, 54 (02) : 215 - 224
  • [27] Niemann-Pick Type C1 deficiency in microglia does not cause neuron death in vitro
    Peake, Kyle B.
    Campenot, Robert B.
    Vance, Dennis E.
    Vance, Jean E.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2011, 1812 (09): : 1121 - 1129
  • [28] Current Challenges in Understanding the Cellular and Molecular Mechanisms in Niemann-Pick Disease Type C1
    Braeuer, Anja U.
    Kuhla, Angela
    Holzmann, Carsten
    Wree, Andreas
    Witt, Martin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (18)
  • [29] Main Olfactory and Vomeronasal Epithelium Are Differently Affected in Niemann-Pick Disease Type C1
    Witt, Martin
    Thiemer, Rene
    Meyer, Anja
    Schmitt, Oliver
    Wree, Andreas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [30] Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropy1-β-cyclodextrin
    Cougnoux, A.
    Clifford, S.
    Salman, A.
    Ng, S. -L
    Bertin, J.
    Porter, F. D.
    MOLECULAR GENETICS AND METABOLISM, 2018, 125 (04) : 345 - 350